Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Drops By 8.9%

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 627,200 shares, a decrease of 8.9% from the September 15th total of 688,800 shares. Currently, 2.1% of the company's shares are short sold. Based on an average daily trading volume, of 96,300 shares, the days-to-cover ratio is presently 6.5 days.

Anixa Biosciences Price Performance

NASDAQ ANIX traded down $0.02 during mid-day trading on Tuesday, hitting $3.03. The company's stock had a trading volume of 67,606 shares, compared to its average volume of 108,740. The firm has a market capitalization of $96.98 million, a P/E ratio of -8.19 and a beta of 0.86. Anixa Biosciences has a 52-week low of $2.14 and a 52-week high of $5.13. The stock's fifty day simple moving average is $3.21 and its two-hundred day simple moving average is $2.96.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its earnings results on Friday, September 6th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. On average, equities analysts forecast that Anixa Biosciences will post -0.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ANIX shares. EF Hutton Acquisition Co. I upgraded Anixa Biosciences to a "strong-buy" rating in a report on Wednesday, August 7th. HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday, September 17th.

Insider Buying and Selling

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. purchased 21,646 shares of the stock in a transaction on Tuesday, July 30th. The stock was bought at an average price of $3.06 per share, for a total transaction of $66,236.76. Following the acquisition, the director now directly owns 890,754 shares of the company's stock, valued at $2,725,707.24. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 22.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Anixa Biosciences

A number of large investors have recently modified their holdings of the stock. Staley Capital Advisers Inc. acquired a new stake in Anixa Biosciences during the 1st quarter valued at $31,000. Concorde Asset Management LLC acquired a new stake in shares of Anixa Biosciences during the second quarter valued at about $31,000. Virtu Financial LLC grew its stake in shares of Anixa Biosciences by 47.2% during the first quarter. Virtu Financial LLC now owns 16,156 shares of the company's stock valued at $50,000 after acquiring an additional 5,183 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV increased its position in shares of Anixa Biosciences by 50.0% during the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company's stock worth $50,000 after acquiring an additional 7,500 shares during the last quarter. Institutional investors and hedge funds own 29.13% of the company's stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.